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I-124 Imaging and Dosimetry
I-124 Görüntüleme ve Dozimetri
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Abstract
Although radioactive iodine imaging and therapy are one of the earliest applications of theranostics, there still remain a
number of unresolved clinical questions as to the optimization of diagnostic techniques and dosimetry protocols. I-124 as
a positron emission tomography (PET) radiotracer has the potential to improve the current clinical practice in the diagnosis
and treatment of differentiated thyroid cancer. The higher sensitivity and spatial resolution of PET/computed tomography
(CT) compared to standard gamma scintigraphy can aid in the detection of recurrent or metastatic disease and provide more
accurate measurements of metabolic tumor volumes. However the complex decay schema of I-124 poses challenges to
quantitative PET imaging. More prospective studies are needed to define optimal dosimetry protocols and to improve patientspecific treatment planning strategies, taking into account not only the absorbed dose to tumors but also methods to avoid
toxicity to normal organs. A historical perspective of I-124 imaging and dosimetry as well as future concepts are discussed.
Keywords: I-124 positron emission tomography/computed tomography, dosimetry, thyroid cancer

Öz
Radyoaktif iyot görüntüleme ve tedavisi teranostiğin ilk uygulamalarından biri olmasına rağmen, halen tanı teknikleri ve
dozimetri protokollerinin optimizasyonu ile ilgili çözümlenmemiş klinik sorular bulunmaktadır. Pozitron emisyon tomografi
(PET) radyofarmasötiği olarak I-124, mevcut klinik uygulamada diferansiye tiroid kanserlerinin tanı ve tedavisini geliştirme
potansiyeline sahiptir. Standart gamma sintigrafisi ile karşılaştırıldığında PET/bilgisayarlı tomografinin yüksek duyarlılık ve
uzaysal çözünürlüğü nüks veya metastatik hastalığın saptanmasında yardımcı olabilir ve metabolik tümör hacimlerinin daha
doğru ölçülmesini sağlayabilir. I-124’ün karmaşık bozunma süreci kantitatif PET görüntüleme için zorluklar teşkil etmektedir.
Optimum dozimetre protokollerini tanımlamak ve hastaya özgü tedavi planlama stratejilerini sadece tümör tarafından abzorbe
edilen doza değil normal organlara toksisiteyi önleyecek metotlara dayanarak iyileştirecek prospektif çalışmalara ihtiyaç vardır.
I-124 görüntüleme ve doz ölçümünün tarihsel perspektifi ile gelecekteki kavramlar tartışılmıştır.
Anahtar kelimeler: I-124 pozitron emisyon tomografi/bilgisayarlı tomografi, dozimetri, tiroid kanseri
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Introduction

Twenty-five patients were included in the study. Eight of
the 25 patients showed more positive foci of uptake on
I-124 images than on I-131. I-124 demonstrated the same
number of foci as on I-131 in 16 patients. One patient had
one additional positive focus on I-131 not seen on I-124,
which could not be confirmed as a metastasis. Out of 97
positive foci, I-124 identified 49 that were not seen with
I-131, and I-131 identified one positive focus not seen with
I-124. They concluded that relative to I-131 planar whole
body imaging, I-124 PET identified as many as 50% more
foci of radioiodine uptake suggestive of residual thyroid
tissue and/or metastases in as many as 32% more patients
who had DTC.
In 2015, as part of the THYROPET study, Kist et al. (7)
focused on a subset of patients with suspected recurrence
from DTC, based on an increased thyroglobulin level and
negative neck ultrasound. All patients underwent I-124
PET/CT after rhTSH stimulation. Subsequently, after 4-6
weeks of thyroid hormone withdrawal, the patients were
treated with 150-200 mCi of I-131 and underwent a planar
whole body scan (WBS) one week later. The study was
terminated preliminarily after inclusion of 17 patients.
Eight post-therapy WBS were negative (47%), all of which
were correctly predicted by a negative I-124 PET/CT. Nine
post-therapy WBS showed RAI avid tumor, of which only
four also had positive I-124 PET/CT findings. The authors
observed that 29% of patients (5/17) would have been
denied potentially effective RAI therapy if I-124 PET/
CT was implemented. Of the false negative lesions with
anatomical correlates on CT, the majority were located in
the lungs. They concluded that the high false negative rate
of rhTSH stimulated I-124 PET/CT precludes its use as a
scouting procedure in this cohort of patients. The authors
postulate that their observed false negative rate may have
been influenced by the 2 mCi dose of I-124 as compared to
the higher doses of I-131 and the use of rhTSH instead of
thyroid hormone withdrawal.
In 2016, our group conducted a phase I/II study to
determine the imaging characteristics and clinical feasibility
of I-124 PET/CT for the determination of disease extent and
evaluation of RAI kinetics in its physiologic and neoplastic
distribution in patients with DTC (8). Fifteen patients were
included in the study. All patients who had I-124 imaging
subsequently underwent RAI treatment with administered
activities of I-131 in the range of 100 to 300 mCi. Posttreatment planar whole body and static images were
obtained 5 to 7 days after RAI treatment and used as a
reference to compare with the pre-treatment I-124 PET/
CT scans. Forty-six distinct lesions were identified in these
15 patients on I-124 PET/CT images with a sensitivity of
92.5%. I-124 identified 22.5% more foci of RAI avid lesions
as compared to the planar I-131 post-treatment scans. In
addition, the I-124 images provided discriminating details
in terms of location and laterality of remnant thyroid
tissue even when no remnant tissue was appreciated on

The mainstay of current clinical radioactive iodine (RAI)
imaging and dosimetry utilizes the radioisotope I-131. The
physical half life of I-131 is 8.02 days that allows imaging
and data acquisition at sequential time points over a
period of several days. The high energy gamma emissions
of 364 keV, however, are a drawback due to poor image
quality resulting in less than optimal evaluation of extent
of disease and quantitation. Another factor contributing
to poor image quality is the relatively small administered
activities in the range of 2-5 mCi. The clinical safety/
efficacy of higher administered activities of I-131 has been
questioned due to concern for the “stunning effect” when
it is used prior to RAI treatment. I-131 remains the standard
treatment for differentiated thyroid cancer (DTC) because
of its beta emissions with a maximum energy of 606 keV
and tissue penetration of 0.6-2 mm.
I-123 is predominantly a gamma emitter with an energy
of 159 keV, which is near the optimal range for standard
gamma camera imaging. In addition, higher administered
activities can be used as compared to I-131 because of less
concern for stunning. Although the physical properties of
I-123 contribute to improved image quality, there are also
several drawbacks. I-123 is is more expensive and is not as
widely available as I-131. The absence of beta decay does
not permit the use of I-123 for therapeutic applications,
and the relatively short half life of 13 hours limits its utility
for dosimetry protocols.
I-124 is a PET radiopharmaceutical with a 4.2-day half life.
It offers superior imaging characteristics with enhanced
spatial resolution and image sensitivity due to coincidence
detection on PET cameras. I-124 also has a favorable half
life that permits the evaluation of in-vivo iodine kinetics.
However, I-124 has a rather complex decay schema, which
creates challenges in optimal imaging. There exist a number
of reports attesting the potential clinical benefits of I-124
imaging in patients with DTC, however, a uniform clinical
protocol for imaging, image analysis and quantitation has
not yet been firmly established.

History of I-124 in Clinical Practice
The use of I-124 in clinical practice in a patient with DTC was
first described in 1960 (1), and the first PET-based dosimetry
study based on serial measurements in DTC patients was
published in 1999 (2) after phantom studies demonstrated
that quantification was feasible (3). Since then, there have
been several key articles demonstrating the clinical utility of
I-124 and its role in the detection of residual thyroid tissue
and/or metastasis in patients with DTC (4,5,6,7,8); and the
following are some more recent highlights.
In 2010, Van Nostrand et al. (6) compared the ability of
I-124 PET versus I-131 planar whole body imaging in
detecting residual thyroid tissue and/or metastatic DTC.
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also been described for other PET radiotracers with longer
half lives such as Y-86 and Br-76 (9,10). Multiple correction
methods have been suggested to address this background
activity but their effectiveness is limited in the setting of
the low count rates observed on clinical I-124 scans. In
addition, the large amount of gamma emissions leads to
higher random coincidence rates, increased dead time and
inaccurate dead time correction (10). Improved gamma
coincidence correction and dead time correction methods
are necessary to ensure accurate quantitative imaging of
I-124 (11).

anatomical imaging. Our group concluded that I-124 PET/
CT is a valuable clinical imaging tool/agent, in both extent
of disease evaluation in the setting of metastatic DTC and
the functional volumetric and kinetic evaluation of target
lesions.

I-124 Properties and Decay Schema
I-124 is cyclotron produced and because of its 4.2-day half
life can be easily transported for clinical use. I-124 has a
positron abundance (number of positrons emitted per decay)
of only 23% with maximum and mean positron energies
of 2138 and 819 keV, respectively. In contrast, the most
common PET radiotracer, F-18, has a positron abundance of
97% with maximum and mean positron energies of 634 and
250 keV, respectively. It is estimated that this high positron
emission energy results in a spatial resolution loss of about
1 mm compared to F-18 FDG which has a spatial resolution
on the order of 5-10 mm depending on the scanner and
clinical reconstruction parameters (3).
In addition to positron emissions, I-124 emits a rather large
portion of gamma rays during its decay, over half of which
have an energy of 603 keV (Table 1). Coincidences of this
604 keV photon and a 511 keV annihilation photon cannot
be distinguished from the true coincidences involving two
511 keV annihilation photons. These gamma coincidences
result in background activity on the PET images which has

Background of Radioactive Iodine Dosimetry
The general principle of RAI dosimetry relies on the premise
that administered activities for diagnostic or therapeutic
purposes should be as low as reasonably achievable to
limit the radiation burden to the individual as well as the
general population. RAI treatment is one of the earliest
applications of theranostics and is certainly a strong
therapeutic intervention, along with surgical treatment, in
the management of DTC. The term “ablation” is used when
RAI is given to destroy residual thyroid tissue in the absence
of functioning thyroid cancer. The term “therapy” refers to
administration of RAI for residual, recurrent or metastatic
DTC. Although RAI therapy is generally well tolerated,
serious side effects can occur and may be deterministic

Table 1. I-124 simplified decay schema and main emissions
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(severity increases with dose and threshold dependent) or
stochastic (occur by chance and non-threshold dependent).
Deterministic effects of RAI therapy can be early and
usually transient (i.e. gastritis, sialadenitis, hypospermia or
amenorrhea) or late (i.e. sicca syndrome, lung fibrosis or
bone marrow depression). Secondary malignancy is the
main stochastic effect of RAI therapy although the incidence
is relatively low and comparable to other modalities such as
external radiotherapy.
The activity to be used for RAI therapy remains a subject of
discussion. Although an empiric fixed-dose RAI treatment
protocol is still in common use, the therapeutic profile of
RAI is best achieved by application of dosimetry-guided,
patient-specific treatment planning. Two approaches for
RAI dosimetry have been applied in clinical practice: the
maximum safe dose approach which was first introduced
by Benua and Leeper and is aimed at administering the
highest amount of I-131 which does not result in bone
marrow suppression (<2 Gy absorbed dose to the bone
marrow with a whole body retention <4.44 GBq at 48
hours) (12,13) and the lesion-based dosimetry method
based on the data by Maxon et al. (14,15) in which a
target dose (at least 80 Gy to metastatic sites and 300 Gy
to thyroid remnants) is calculated on the basis of planar
diagnostic I-131 scanning.
The maximum safe dose approach focuses on the safety
of RAI treatment. Blood is used as a surrogate of the red
bone marrow, which is considered as the critical organ in
this approach. Over the years, the original Benua method
was refined with improved patient specificity using Medical
Internal Radiation Dose (MIRD) methodology. Strengths of
the blood-based dosimetry approach include determination
of the maximum safe activity of RAI for each individual
patient, identification of patients for whom empiric fixed
activities are not considered safe, and the potential to
administer higher activities at once instead of multiple
fractions of lower activity in order to avoid changes in
tumor/lesion biokinetics. Although there is a long history of
using this treatment strategy at multiple institutions, there
is a paucity of clinical data to show improved response or
outcome rates. In addition, the absorbed dose to the tumor
is not known in this approach and although controversial,
there is a risk of stunning with dosimetric administrations
of I-131 that may alter tumor/lesion biokinetics during
subsequent treatment (16).
The objective of lesion-based dosimetry is to determine
the RAI activity that delivers the recommended absorbed
dose of radiation to ablate thyroid remnants or treat
metastatic disease while minimizing the risk to patients.
The calculation of lesion dose is generally based on MIRD
methodology and for smaller lesions the spherical model of
OLINDA/EXM can be employed. In lesion-based dosimetry,
not only is it important to determine how much activity
is contained within the lesion, it is also necessary to
calculate the mass of the lesion. This can be challenging

especially for ablation purposes as measuring the size of
thyroid remnants is often not reliable using anatomical
imaging such as ultrasound or computed tomography
(CT). Some disadvantages of a lesion-based approach to
RAI treatment include the wide range of absorbed doses
to lesions within a given patient and the inhomogeneous
absorbed dose distributions and lack of accurate models to
reflect RAI kinetics within individual lesions (16). Since the
accuracy of all dosimetric approaches relies on the accurate
quantitation of RAI kinetics, I-124 being a PET radiotracer
with enhanced spatial resolution may play a pivotal role in
this area.

I-124 Dosimetry Protocols and Clinical Applications
Why is I-124 well-suited for RAI dosimetry? Of the available
radio-iodine isotopes, I-123 would be the preferred agent
for dosimetry given its photopeak that is close to the
optimal range for gamma camera imaging; however, its
relatively short half life precludes imaging at sequential time
points in a practical manner. I-131 is relatively inexpensive,
is widely available and has become the mainstay of RAI
dosimetry. However, only small administered activities
can be given because of the risk of stunning. Additionally
the high energy gamma emissions result in poor image
quality. I-124 behaves biochemically similar to I-131 and its
physical half life of 4.2-days makes it suitable for sequential
time point imaging and absorbed dose calculations. With
I-131 planar imaging, there is uncertainty regarding RAI
avid lesion dimensions, and with single-photon emission
computed tomography (SPECT), the counting rate at
diagnostic activity levels is inadequate for accurate
quantification. Given the added benefit of PET/CT with
I-124, not only can fine details be discriminated that are
not visible on low-dose planar imaging but also areas of
radiotracer uptake can be detected that do not have a
measurable anatomical correlation on CT (such as with
thyroid remnants as observed in our study). However, there
are drawbacks of using I-124 for RAI dosimetry including
its relatively high cost and complex decay schema, which
may lead to background noise and voxel oversaturation
even at low administered activities.
Several investigational studies have successfully used I-124
PET alone and with CT to guide postsurgical treatment and,
in particular, RAI therapy in patients with DTC. The number
of measurement time points varies for each I-124 dosimetry
protocol described in the literature (17,18,19,20,21,22,23).
An important observation that should be highlighted is the
high intra- and inter-lesional variability in RAI avid tumors
(18) as well as in normal tissues such as salivary glands
(24,25).
Our group demonstrated different kinetic profiles for
normal thyroid remnants, salivary glands, and metastatic
lesions as well as individual variations in functional
volumes, and thus cumulated activities (8). The sequential
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and beta emissions from the bone marrow to the bone
marrow. The S values are obtained from anthropomorphic
phantoms and assume uniform distribution of activity
within a source organ of defined geometry.
Our group applied the MIRD schema to define a protocol
for I-124 dosimetry. The protocol involves acquiring whole
body PET/CT images and blood samples at 4 different
time points, i.e. 4, 24, 48 and 72 hours following the
administration of a 2 mCi dose of I-124. Regions of interest
were drawn around the whole body at each time point in
order to generate a time activity curve for the whole body
compartment. Similarly, I-124 counts were measured from
the blood samples at each sequential time point to generate
a time activity curve for the bone marrow compartment
(assuming a uniform distribution of blood within the bone
marrow). Cumulated activities and residence times for the
whole body and bone marrow compartments were then
obtained by calculating the area under each respective
time activity curve. The target organ in this case is the bone
marrow since the goal of dosimetry-guided RAI treatment
is to deliver the maximum permissible dose to the patient
without permanent damage to the bone marrow. The
source organs are the whole primarily (primary in the form
of gamma emissions) and the bone marrow (primarily in
the form of beta emissions). The absorbed dose to the
target organ is the sum of the cumulated activities from
the source organs multiplied by their respective S values.
What are some drawbacks of this method? One drawback
of the traditional MIRD schema is that the absorbed dose
to the tumor is not routinely calculated. Given the wide
range of dose variability within a tumor, one cannot be
confident (based on bone marrow dosimetry alone) that a
lesion will receive a sufficient dose to produce the desired
tumoricidal effect. Another limitation revolves around the
use of the S values which are derived from anthropomorphic
phantoms with uniform activity distribution and defined
geometry. Although this is generally acceptable for bone
marrow dosimetry (with only two source organs), it is not
applicable for lesion-based dosimetry where commonly
lesions are encountered with complex shapes and nonuniform distributions of activity. A distinct advantage
of I-124 dosimetry lies in its application for lesion-based
dosimetry where the higher resolution PET/CT images
allow for improved lesion contouring and quantification.
Our group demonstrated that there is a significant variation
in cumulated activities within individual lesions, whether
the lesions depict normal physiologic uptake (as in the
salivary glands or thyroid remnants) versus metastatic foci
(8). These variations in cumulated activities clearly alter
the dosimetric input and cannot be distinguished using
traditional I-131 techniques.
For complex lesions which cannot be evaluated using
standard anthropomorphic phantoms, voxel-based can be
employed, which utilizes or not Monte Carlo based codes.
In the simplest voxel-based dosimetry, a lesion (whether it

I-124 PET/CT images consistently demonstrated the
maximum activity within thyroid remnant tissue to
occur at 24 hours. After the peak activity was reached,
the clearance was mono-exponential. The maximum
remnant activity ranged from 0.044 to 7.988 MBq with
the total functional remnant volume (the total number
of voxels within the remnant ROI) ranging from 1 to 60
ml. Physiologic activity within the salivary glands reached
a peak at 4 hours after radioiodine administration. The
salivary gland clearance was bi-exponential with an
average of 81% of the activity being cleared from the
salivary glands by 24 hours. In contrast, metastatic disease
to lymph nodes demonstrated an uptake pattern that
was significantly different than the thyroid remnant or
physiologic salivary gland activity. A progressive increase
in activity with protracted retention was identified as
a characteristic pattern for metastatic nodal disease.
The remnant data is particularly interesting as it again
highlights the potential value of individualized patientspecific dosimetric assessment even for purposes of
thyroid remnant ablation rather than an empiric or “one
dose fits all” approach. However, a larger scale remnant
dosimetry study is required to address this issue.
Why do we need RAI dosimetry? Although many centers
have adapted a fixed-dose of I-131 in the range of 100200 mCi for the treatment of metastatic DTC, there are
several drawbacks to using this empiric technique. Without
knowledge of the rate of radiobiological clearance as well
as the degree of intra-lesion variability in absorbed dose,
a proportion of patients will be over- or under-treated
using an empiric dose of I-131. Benua et al. (12) observed
that repeated sub-therapeutic doses of RAI might induce
dedifferentiation and loss of iodine-concentrating ability of
tumors. The rationale of using the highest possible dose
is based on the radiobiologic fact that radiation treatment
efficacy is directly related to the radiation dose delivered.
Therefore, the goal of dosimetry-guided RAI therapy is to
derive a patient-specific dose that will deliver the highest
possible tumoricidal effect to metastatic sites while
minimizing toxicity to normal tissues. Another potential
application of RAI dosimetry involves the ablation of thyroid
remnants where the goal is to deliver the lowest possible
ablative dose taking into account patient-specific factors
such as the functional volume of thyroid tissue remaining
as well as the variability in dose distribution.

Technical Considerations of I-124 Dosimetry
Traditional I-131 dosimetry using MIRD methodology
involves sequential time point whole body imaging and
blood sampling to obtain time activity curves and residence
times for the whole body and bone marrow compartments.
The classic formula D= xS, takes into account the cumulated
activities derived from both compartments incorporating
gamma emissions from the whole body to the bone marrow
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Applying MC codes in I-124 dosimetry is another area
of future investigation. MC codes for particle transport
pursue the calculation of the random walk, or the track,
of (numerical) particles analogous to what would occur
in reality. I-124 imaging intrinsically gives information of
iodine position and concentration and, therefore, can be
used as a surrogate for other iodine isotopes if isotopical
correlation and decay correction coefficients are known.
Consequently, having iodine distribution defined from I-124
imaging, one can feed the model with decay information of
I-124 as well as from other iodine isotopes (considering the
mentioned corrections) and obtain dose distributions for
isotopes such as I-131.
The combination of MC codes and data from I-124 PET/
CT studies can help develop patient- and compoundspecific numerical models for 3D dosimetry evaluations
(31,32). This type of dosimetry can involve triple voxelized
models with resolutions as good as imaging studies allow:
voxelized geometry utilizing CT data, voxelized emission
distribution utilizing PET data, and voxelized distributions of
dose estimators. This means that one can reach optimized
resolutions in three aspects: geometry of the regions of
interest, source distribution, and detection.
Utilizing this modality, one can assess more realistic particle
transport and more representative dose values for large
and small regions. The voxelized dose estimators are an
important tool for defining hot and cold spots and they
provide data for construction of dose-volume histograms
or other dosimetry analysis tools. A great advantage of this
modality is that it allows for accurate estimation of volumerepresentative dose values. This means one can determine
the volume of influence of a certain dose. For example,
if bone marrow is considered, one can determine the
maximum, mean, and minimum dose and what fraction of
the marrow would receive more than the tolerance dose.
Great contrast appears if this dosimetry modality is compared
to previous methods such as those based on the utilization of
generic numerical phantoms, e.g. OLINDA/EXM (33), where
geometry is not patient specific, organs are considered
uniform, emitters are assumed homogeneously distributed
in tissues, and doses are whole organ averages. This is also
in contrast with more recent modalities based on patientspecific PET/CT images that do not perform the particle
transport for each case but utilize standardized fixed pointdose kernels, voxel-dose kernels or other approximations
(34). In some cases, the differences are not important but,
when heterogeneities are present, large differences might
appear. This can be the case for regions with tissue changes
or with large activity gradients such as in thyroid remnants.

be normal tissue, an individual tumor or a region within
a tumor) is divided into voxels of the same 3-dimensional
geometry. MIRD formalism is then applied so that the
cumulated activity is calculated for each individual voxel
comprising the lesion. Each voxel has an assigned S value
based on the radioisotope and its location within the lesion,
which is assumed to be a homogeneous tissue medium.
The absorbed dose to a target lesion is then calculated by
summing the products of the cumulated activities and S
values of the individual source voxels in a 3-dimensional
array (34). The S values are precalculated standarized
parameters which do not consider patient-specific tissue
heterogeneities. In this case they represent point-dose or
voxel-dose kernels. They can be calculated through MC
methods (in this case the dosimetry might be considered
a type of MC based dosimetry) or through deterministic
ones.
MC transport codes can take lesion-based dosimetry to
another level by addressing tissue inhomogeneity and
assessing their influence on the resulting dose distributions.
Target lesions are again divided into iso-volumetric voxels
and the cumulated activities are calculated for each
individual voxel. However, instead of utilizing S values
kernels from standarized uniform tissues, MC based fully
developed dosimetries utilize a more complex approach.
MC codes can incorporate the probabilistic interactions of
radiation with matter including multiple different particles
(beta, gamma, photoelectric absorption, Compton scatter
and electron-positron pair production) contributing to the
absorbed target dose from multiple different pathways that
are modeled by computer program computations. MC codes
together with appropriate physical data and modeling can
provide the most realistic numerical evaluations. Amongst
the most evolved, complete and reliable codes of this type
are MCNP6 (26), GEANT4 (27,28), and FLUKA (29,30).

Future I-124 Dosimetry Concepts
Areas of future investigation for I-124 dosimetry involve
issues related to data collection and data processing. It is
widely accepted that 4 time points are required for accurate
curve fitting models in order to calculate the cumulated
activity. Can this method be streamlined so that fewer time
points are needed to generate similar time activity curves
with minimal effect on the cumulated activity? This may be
plausible given the shorter half life of I-124 as compared
to I-131. Another area that our group is focusing on
involves the identification of a surrogate for bone marrow
activity on anatomical imaging rather than relying on blood
sampling. Can a region of interest be drawn on PET/CT
(for example around the aorta, vertebral bodies or soft
tissues) to simulate the activity within the bone marrow
compartment? Our preliminary data indicates that this is
likely feasible but a larger patient population is needed for
statistical power.

Conclusions
There are a number of ways in which I-124 PET/CT may
contribute to current clinical practice in the management of
patients with DTC. Studies have shown that I-124 PET/CT is
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a superior imaging agent as compared to diagnostic I-131
planar whole body scintigraphy with lesion detectability
similar to post-treatment I-131 scans. In addition, the
potential applications of quantitative I-124 PET/CT imaging
for RAI treatment planning have been described that show
similar benefits over traditional I-131 dosimetry techniques.
However, due to the physical properties of I-124 and its
complex decay schema, there remains a need for improved
correction methods to ensure the accuracy of diagnostic
images and quantitative analysis. Also, there is a need for
larger prospective trials to address the number and timing
of scans needed for optimal dosimetry protocols. Despite its
benefits in lesion detection and measurement of metabolic
tumor volumes, for I-124 to be used mainstream, it needs
to be more commercially available and at a lower cost.
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